Jonathan Eskenazi, MD
Neurology · West Hollywood, CANPI 1568894988
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 34.0% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,618 payments — averaging $61.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Teva Pharmaceuticals USA, Inc.$20K
- Amgen$10K
- SK Life Science, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- UCB, Inc.$2K
- plus $28K from 54 others
Across 13 payments — averaging $5787.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$39K
- Amgen$19K
- Jazz Pharmaceuticals Inc.$10K
- Sanofi$8K
What the payments were for
- Consulting fees$1,9002%
- Speaking & faculty fees$49,54050%
- Travel & lodging$1,6132%
- Food & beverage$46,54147%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,709 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 363 | $8,679,181 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 108 | $2,581,520 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 104 | $1,884,696 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 28 | $957,119 |
| NamzaricMemantine Hcl/Donepezil Hcl | 355 | $222,727 |
| UbrelvyUbrogepant | 216 | $219,929 |
| Emgality PenGalcanezumab-Gnlm | 215 | $175,120 |
| IngrezzaValbenazine Tosylate | 21 | $167,774 |
| Nurtec OdtRimegepant Sulfate | 95 | $89,851 |
| QuliptaAtogepant | 75 | $79,560 |
| BriviactBrivaracetam | 50 | $73,664 |
| CopaxoneGlatiramer Acetate | 12 | $70,004 |
| AptiomEslicarbazepine Acetate | 47 | $64,402 |
| HorizantGabapentin Enacarbil | 92 | $55,585 |
| Lidocaine | 855 | $52,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $618 | $8,679,181363 claims |
| PfizerOctagam, Panzyga, Nurtec Odt | $193 | $3,628,489231 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta | $33,895 | $522,216646 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,443 | $167,77421 claims |
| UCB, Inc.Briviact, Neupro | $2,356 | $88,82468 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $19,597 | $70,00412 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $99 | $64,40247 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $57 | $55,58592 claims |
| SK Life Science, Inc.Xcopri | $2,521 | $34,56136 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $386 | $31,57882 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $717 | $19,85718 claims |
| Neurelis, Inc.Valtoco | $692 | $14,18211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in West Hollywood
- Regina BerkovichWest Hollywood$3M
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.